The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Dec. 12, 2017
Applicants:

Battelle Memorial Institute, Richland, WA (US);

University of Washington, Seattle, WA (US);

Inventors:

Wei-Jun Qian, Richland, WA (US);

Tujin Shi, Richland, WA (US);

Alvin Y. Liu, Everett, WA (US);

Assignees:

Battelle Memorial Institute, Richland, WA (US);

University of Washington, Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); G01N 33/68 (2006.01); C12Q 1/37 (2006.01); C12Q 1/533 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C12Q 1/37 (2013.01); C12Q 1/533 (2013.01); C12Y 304/24035 (2013.01); C12Y 503/04001 (2013.01); G01N 33/57434 (2013.01); G01N 33/6848 (2013.01); G01N 33/6863 (2013.01); G01N 33/6869 (2013.01); G01N 2333/47 (2013.01); G01N 2333/52 (2013.01); G01N 2333/54 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/96486 (2013.01); G01N 2333/99 (2013.01);
Abstract

Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.


Find Patent Forward Citations

Loading…